Structure-activity relationships of indole- and pyrrole-derived cannabinoids

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 995-1004

  Wiley, Jenny L ^a,c   Compton, David R ^a   Dai, Dong ^b   Lainton, Julia A H ^b   Phillips, Michelle ^b   Huffman, John W ^b   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CLEMSON UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR; CARBONYL DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BINDING AFFINITY; BINDING SITE; CATALEPSY; DRUG RECEPTOR BINDING; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CANNABINOIDS; DISCRIMINATION LEARNING; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031864382     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Adams IB, Compton DR and Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
2. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62.
3. Binder M and Franke I (1982) Is there a THC receptor?: Current perspectives and approaches to the elucidation of the molecular mechanism of action of the psychotropic constituents of cannabis sativa L, in Neuroreceptors (Hucho F, ed) pp151-161, Walter de Gruyter & Co., Berlin.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Compton DR, Gold LH, Ward SJ, Balster RL and Martin BR (1992) Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126.
6. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR and Martin BR (1993) Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
7. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK and Daley GT (1992) Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124-135.
8. Devane WA, Dysarz III FA, Johnson MR, Melvin LS and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
10. Dewey WL, Harris LS, Howes JF and Nuite JA (1970) The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J Pharniacol Exp Ther 175:435-442.
11. Edery H, Grunfeld Y, Ben-Zvi Z and Mechoulam R (1971) Structural requirements for cannabinoid activity. Ann N Y Acad Sci 191:40-53.
12. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM, Wetzel JR, Alexander MD, Weaver III JD, Haycock DA, Luttinger DA, Casiano, FM, Chippari SM, Kuster JE, Stevenson JI and Ward SJ (1995) Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J Med Chem 38:3094-3105.
13. Fan F, Compton DR, Ward S, Melvin L and Martin BR (1994) Development of cross-tolerance between Δ9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271:1383-1390.
14. Haubrich DR, Ward SJ, Baizman E, Bell MR, Bradford J, Ferrari R, Miller M, Perrone M, Pierson AK, Saelens JK and Luttinger D (1990) Pharmacology of pravadoline: A new analgesic agent. J Pharmacol Exp Ther 255:511-522.
15. Huffman JW, Dai D, Martin BR and Compton DR (1994) Design, synthesis and pharmacology of Cannabimimetic indoles. Biomed Chem Lett 4:563-566.
16. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD and Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877.
17. Lainton JAH, Huffman JW, Martin BR and Compton DR (1995) 1-Alkyl-3-(1-naphthoyl)pyrroles: A new class of cannabinoid. Tetrahedron Lett 36:1401-1404.
18. Martin BR, Balster RL, Razdan RK, Harris LS and Dewey WL (1981) Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci 29:565-574.
19. Martin BR, Compton DR, Prescott WR, Barrett RL and Razdan RK (1995) Pharmacological evaluation of dimethylheptyl analogs of Δ9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend 37: 231-240.
20. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
21. Pério A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G and Soubrié P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65-71.
22. Pertwee RG (1972) The ring test: a quantitative method for assessing the "cataleptic" effect of cannabis in mice. Br J Pharmacol 46:753-763.
23. Pertwee RG, Griffin G, Lainton JAH and Huffman JW (1995) Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur J Pharmacol 284:241-247.
24. Pertwee RG, Stevenson LA and Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the Cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 110:1483-1490.
25. Petitet F, Marin L and Doble A (1996) Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. Neuroreport 7:789-792.
26. Razdan RK (1986) Structure-activity relationships in cannabinoids. Pharmacol Rev 38:75-149.
27. Reggio PH, Greer KV and Cox SM (1989) The importance of the orientation of the C9 substituent to cannabinoid activity. J Med Chem 32:1630-1635.
28. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Breli 138 re JC and Le Fur G (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
29. Ryan WJ, Banner WK, Wiley JL, Martin BR and Razdan RK (1997) Potent anandamide analogs: The effect of changing the length and branching of the end pentyl chain. J Med Chem 40:3617-3625.
30. Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, Mccallion DS, Pertwee RG, Compton DR and Martin BR (1997) Synthesis and pharmacological comparison of dimethylheptyl and pentyl anandamide analogs. J Med Chem 40:3626-3634.
31. Showalter VM, Compton DR, Martin BR and Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999.
32. Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896.
33. Tallarida RJ and Murray RB (1987) Manual of Pharmcologic Calculations with Computer Programs. 2nd ed, Springer-Verlag, New York.
34. Thomas BF, Adams IB, Mascarella SW, Martin BR and Razdan RK (1996) Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem 39:471-479.
35. Thomas BF, Compton DR, Martin BR and Semus SF (1991) Modeling the cannabinoid receptor: A three-dimensional quantitative structure-activity analysis. Mol Pharmacol 40:656-665.
36. Wiley JL, Huffman JW, Balster RL and Martin BR (1995a) Pharmacological specificity of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend 40:81-86.
37. Wiley JL, Lowe JA, Balster RL and Martin BR (1995b) Antagonism of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.